Investigating the effect of a supplement of hydroalcoholic extract of Eryngium on the metabolic marker in type 2 diabetic patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181006041252N7

Enrollment

Registered

2019-01-25

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: Patients in this group are treated with Hydroalcoholic extract of Eryngium (10 drops 3 times a day) for 3 months. (Each ml (28 drops) of this drug contains 924 mg o

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Type 2 diabetes for at least 2 years HbA1C less than 8.5 Patients aged 20-60 years Non-insulin treated diabetic patients

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Renal and cardiovascular disorders and chronic underlying disease Insulin therapy Micro and macro-vascular diabetic complications Use of other herbal medicines that have an effect on diabetes Smoking or alcohol abuse within a month before the study.

Design outcomes

Primary

Measure	Time frame
Determine Fasting Blood Sugar (FBS). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Glycosylated Hemoglobin (HbA1C). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Triglyceride. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Cholesterol. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Low-density Lipoprotein (LDL). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of High-density Lipoprotein (HDL). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Creatinine. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Urea. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Alkaline Phosphatase. Timepoint: At the beginning of the study (before	—

Measure

Time frame

Determine Fasting Blood Sugar (FBS). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Glycosylated Hemoglobin (HbA1C). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Triglyceride. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Cholesterol. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Low-density Lipoprotein (LDL). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of High-density Lipoprotein (HDL). Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Creatinine. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Urea. Timepoint: At the beginning of the study (before the intervention) and 3 months after starting the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Alkaline Phosphatase. Timepoint: At the beginning of the study (before

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fereshte Ghorat

Sabzevar University of Medical Sciences

Drghorat@gmail.com+98 51 4401 8337

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026